A chance to delay or prevent the disease entirely
For generations, type 1 diabetes has been met only after it arrives — managed, never forestalled. Now, for the first time, the NHS in England and Wales has approved a drug that intervenes before the diagnosis, offering at-risk individuals a chance to delay the autoimmune process that destroys insulin-producing cells. Teplizumab, the first disease-modifying therapy of its kind on the NHS, repositions medicine not as a response to illness but as a quiet negotiation with its approach.
- Teplizumab breaks new ground as the first NHS-approved therapy to target the underlying cause of type 1 diabetes before symptoms ever appear.
- Clinical trials showed the drug delays diabetes onset by an average of three years — years without insulin injections, blood glucose monitoring, or the weight of chronic disease management.
- England now leads Europe in funding this preventive treatment, placing the UK ahead of other nations in a race to redefine early intervention for a condition affecting thousands of children.
- The NHS must now expand screening programmes and build new clinical pathways to identify at-risk patients — those with family histories or detectable autoimmune markers — before the window for intervention closes.
- The drug is not a cure, and many patients will still develop diabetes eventually, but the delay it offers can be transformative, particularly for children gaining years of uninterrupted health.
For the first time, the NHS will offer a drug that delays the onset of type 1 diabetes rather than simply managing it after diagnosis. Teplizumab, marketed as Tzield by Sanofi, has been approved across England and Wales — a meaningful shift in how medicine approaches one of the most common chronic conditions in children.
Type 1 diabetes occurs when the immune system attacks the pancreas's insulin-producing cells. Once that process begins, it cannot be reversed. Teplizumab works by modulating the immune response, slowing the autoimmune attack in people identified as at-risk before any symptoms appear. It is the first disease-modifying therapy the NHS has approved that targets the disease process itself, rather than its consequences.
Clinical trials demonstrated the drug can delay diabetes onset by an average of three years. For a child, that delay is not a small thing — it means years without daily injections, without constant blood glucose monitoring, without the vigilance chronic illness demands. England's decision to fund the treatment positions the country ahead of other European nations in accessing this preventive approach.
The rollout will require the NHS to think about diabetes differently — not as something to treat after it appears, but as something to intercept beforehand. That means expanding screening, training clinicians to identify at-risk patients, and building pathways to deliver the drug to those who need it most. For thousands of families living with type 1 diabetes in the UK, the approval signals that prevention has, at last, become possible.
For the first time, the NHS will offer a drug that can actually delay the onset of type 1 diabetes rather than simply manage it after diagnosis. Teplizumab, marketed under the brand name Tzield by pharmaceutical company Sanofi, has been approved for rollout across England and Wales, marking a shift in how the health service approaches one of the most common chronic conditions in children.
Type 1 diabetes occurs when the immune system mistakenly attacks the insulin-producing cells in the pancreas. Once that process begins, it cannot be reversed—patients require insulin injections for life. What makes teplizumab different is that it can slow or postpone that autoimmune attack in people identified as at-risk before symptoms appear. The drug works by modulating the immune response, giving the body's remaining insulin-producing cells more time to function.
This approval represents a genuine departure from existing diabetes care. Until now, treatment has focused on managing blood sugar levels after diagnosis. Teplizumab is the first disease-modifying therapy the NHS has approved that targets the underlying disease process itself, before the patient becomes diabetic. For families with a history of type 1 diabetes, or for individuals identified through screening as having the autoimmune markers that precede diagnosis, this offers something previously unavailable: a chance to delay or prevent the disease entirely.
England's decision to fund teplizumab through the NHS positions the country ahead of other European nations in accessing this preventive treatment. The approval comes after clinical trials demonstrated that the drug could delay diabetes onset by an average of three years in at-risk patients. That delay matters enormously—it means years without daily insulin injections, without blood glucose monitoring, without the constant vigilance required to manage a chronic condition. For a child, three additional years of normal childhood before diagnosis can be transformative.
The rollout will focus on identifying and treating at-risk individuals—those with family members who have type 1 diabetes, or those found through screening to have the autoimmune markers that signal the disease process has begun. This requires a shift in how the NHS thinks about diabetes: not as something to treat after it appears, but as something to intercept before symptoms develop. It means expanding screening programs, training clinicians to recognize at-risk patients, and establishing pathways to deliver the drug to those who need it.
For the thousands of families affected by type 1 diabetes in the UK, the approval signals that prevention is now possible. The drug is not a cure—eventually, many patients will still develop diabetes—but the delay it provides can mean years of better health, fewer complications, and more time before the demands of managing a chronic condition begin. The NHS rollout will determine how many at-risk individuals actually receive the treatment and whether the health service can successfully identify and reach them before diagnosis occurs.
Citas Notables
The drug can delay diabetes onset by an average of three years in at-risk patients— Clinical trial data
La Conversación del Hearth Otra perspectiva de la historia
So this drug doesn't cure type 1 diabetes—it just delays it. Why is that worth celebrating?
Because three years is not nothing. For a child, that's the difference between getting diagnosed at seven or at ten. It's years of normal blood sugar, no insulin injections, no constant monitoring. And we don't know what happens in those three years—the immune system changes, new treatments might emerge.
But eventually they still get diabetes?
In most cases, yes. The drug slows the autoimmune attack, but it doesn't stop it permanently. But delaying onset means delaying all the complications that come with it—the eye damage, the kidney damage, the nerve damage. Every year you can push that back matters.
Who actually gets this drug? How does the NHS decide?
That's the real question now. They need to identify at-risk people first—that means screening, which costs money and requires infrastructure. Mostly it'll be people with a family history, or those who've already tested positive for the autoimmune markers. But not everyone will be screened, and not everyone who could benefit will know they're at risk.
So England is ahead of Europe on this. Does that mean other countries will follow?
Probably. Once one major health system approves something and starts funding it, others take notice. But it also depends on cost and whether other countries think the delay is worth the investment. The NHS clearly does.